Compare GSK plc (GSK) vs Match Group Inc (MTCH) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

MTCH trades at $40.71, up 6.18% in the last session, with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with a P/E of 15.31, net income margin of 18.83%, and consistent earnings beats in recent quarters. Operating cash flow grew to $1.08B in 2025, while revenue remains stable at $3.49B. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.

The outlook is positive with a consensus price target of $41.63, implying modest upside. Risks include high long-term debt of $3.85B and declining Tinder users, offset by pricing power and AI features. Institutional sentiment is bullish with no sell ratings, but investors should monitor Q2 earnings for growth sustainability amid competitive pressures.